Anthropic says Claude recovered HAWK-256 signing material and sped up a seven-round AES-128 attack, but neither affects ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

LONDON — An experimental drug can sweep tangles of tau from the brain, raising hopes that the treatment could help Alzheimer’s disease patients, according to clinical trial data released July 14. The ...

Researchers found that tau is essential for turning new experiences into lasting memories by helping organize the brain's memory-storing cells. The mouse study also revealed how abnormal tau may ...

After years of waiting, we're finally heading to Tau in Warframe, but this feels like more than just an update - it's a new chapter. Lauren Bergin News Editor Lauren spends most of her time dead in ...

The South Florida Water Management District's Python Elimination Program rewards hunters for removing the invasive snakes. In May 2026, contracted hunters eliminated 315 python eggs from the ...

Alzheimer's disease is a neurodegenerative disease characterized by a progressive decline in mental functions and memory loss. Along with frontotemporal dementia and some other neurodegenerative ...

Some subscribers prefer to save their log-in information so they do not have to enter their User ID and Password each time they visit the site. To activate this function, check the 'Keep me signed in' ...

Macquarie's Eugene Hsiao discusses the end of Moore's Law after Huawei introduces Tau Scaling Law. He sees convergence of chipmaking paths as the race for more cutting-edge chips continue. Meanwhile, ...

Huawei is proposing a new way to keep the semiconductor industry moving forward at a time when making smaller and smaller chips is becoming increasingly difficult. At the International Circuit Systems ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the Alzheimer’s disease trial failed to yield the hoped-for dose-response data, ...